<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21700">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824380</url>
  </required_header>
  <id_info>
    <org_study_id>DA4001_AGAP_I</org_study_id>
    <nct_id>NCT02824380</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <brief_summary>
    <textblock>
      An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Pharmacokinetics/
      Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects with Androgenic Alopecia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Css,max(Maximum steady state concentration) of Finasteride(ng/mL)</measure>
    <time_frame>day1, 6: before administration, day7: before administration and 0.5, 1, 2, 3, 4, 6, 8, 12, 24h after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau(Area under the plasma concentration versus time curve) of Finasteride (ng·hr/mL)</measure>
    <time_frame>day1, 6: before administration, day7: before administration and 0.5, 1, 2, 3, 4, 6, 8, 12, 24h after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of testosterone and DHT(ng/mL)</measure>
    <time_frame>day1: before administration, day7: before administration and 6, 12, 24h after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tss,max(Time to reach maximal serum concentrations at steady state)of Finasteride(hr)</measure>
    <time_frame>day1, 6: before administration, day7: before administration and 0.5, 1, 2, 3, 4, 6, 8, 12, 24h after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css,min(Minimum steady state concentration)of Finasteride(ng/mL)</measure>
    <time_frame>day1, 6: before administration, day7: before administration and 0.5, 1, 2, 3, 4, 6, 8, 12, 24h after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β(Elimination Half-life) of Finasteride(hr)</measure>
    <time_frame>day1, 6: before administration, day7: before administration and 0.5, 1, 2, 3, 4, 6, 8, 12, 24h after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Androgenic Alopecia</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: DA-4001 H(High dose) Period 2: DA-4001 L(Low dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: DA-4001 L(Low dose) Period 2: DA-4001 H(High dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-4001 H</intervention_name>
    <description>5% minoxidil / high dose of finasteride</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-4001 L</intervention_name>
    <description>5% minoxidil / low dose of finasteride</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, aged between 19 and 65 years, clinically healthy

          -  BMI between 18.5kg/m2 and 27kg/m2

          -  Clinical history of Androgenic Alopecia

        Exclusion Criteria:

          -  Subject has any dermatological disorders of the scalp

          -  Subject has a history of hair transplants, hair weaves

          -  Subject has hypersensitivity to previously prescribed minoxidil or finasteride

          -  Subject who is considered inappropriate to participate in the study due to any
             conditions including screening results at the investigator's discretion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jae Gook Shin, MD, PhD</last_name>
    <email>phshinjg@inje.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Guk Shin, MD, PhD</last_name>
      <email>phshinjg@inje.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 6, 2016</lastchanged_date>
  <firstreceived_date>June 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
